DE69511399T2 - Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren - Google Patents

Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren

Info

Publication number
DE69511399T2
DE69511399T2 DE69511399T DE69511399T DE69511399T2 DE 69511399 T2 DE69511399 T2 DE 69511399T2 DE 69511399 T DE69511399 T DE 69511399T DE 69511399 T DE69511399 T DE 69511399T DE 69511399 T2 DE69511399 T2 DE 69511399T2
Authority
DE
Germany
Prior art keywords
mage
hla
insulated
molecules
derived peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69511399T
Other languages
English (en)
Other versions
DE69511399D1 (de
Inventor
Der Bruggen Pierre Van
Thierry Boon-Falleur
Catia Traversari
Katharina Fleischauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research New York
Publication of DE69511399D1 publication Critical patent/DE69511399D1/de
Application granted granted Critical
Publication of DE69511399T2 publication Critical patent/DE69511399T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69511399T 1994-03-24 1995-03-21 Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren Expired - Lifetime DE69511399T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,187 US5554506A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
PCT/US1995/003408 WO1995025739A1 (en) 1994-03-24 1995-03-21 Isolated, mage-3 derived peptides which complex with hla-a2 molecules and uses thereof

Publications (2)

Publication Number Publication Date
DE69511399D1 DE69511399D1 (de) 1999-09-16
DE69511399T2 true DE69511399T2 (de) 2000-05-11

Family

ID=22810011

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69511399T Expired - Lifetime DE69511399T2 (de) 1994-03-24 1995-03-21 Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren

Country Status (16)

Country Link
US (3) US5554506A (de)
EP (1) EP0759032B1 (de)
JP (1) JP3451356B2 (de)
CN (1) CN1142177C (de)
AT (1) ATE183195T1 (de)
AU (1) AU682956B2 (de)
CA (1) CA2186005A1 (de)
DE (1) DE69511399T2 (de)
DK (1) DK0759032T3 (de)
ES (1) ES2135051T3 (de)
FI (1) FI963781A0 (de)
GR (1) GR3031811T3 (de)
NZ (1) NZ283543A (de)
TW (1) TW496875B (de)
WO (1) WO1995025739A1 (de)
ZA (1) ZA952376B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5827073A (en) * 1995-07-05 1998-10-27 Ludwig Institute For Cancer Research Photoreactive peptide derivatives
US6087441A (en) 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6025470A (en) * 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
ATE377022T1 (de) * 1997-06-23 2007-11-15 Ludwig Inst Cancer Res Isolierte decapeptide, die an hla moleküle binden,sowie deren verwendung
WO2001030382A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
AU2001229681A1 (en) * 2000-01-20 2001-07-31 Ludwig Institute For Cancer Research Mage antigenic peptides which bind hla-b35 and hla-b44
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
PT1496939E (pt) 2002-04-09 2007-11-22 Sanofi Pasteur Ltd ''ácido nucleico de cea modificado e vectores de expressão''
US20070105779A1 (en) * 2002-07-31 2007-05-10 Danila Valmori Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
EP1923463B1 (de) * 2005-08-09 2011-10-05 Oncotherapy Science, Inc. Von glypican-3 (gpc3) abgeleitetes krebsabstossungsantigen-peptid zur verwendung bei einem hla-a2-positiven patienten und das antigen enthaltendes arzneimittel
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP1704868A1 (de) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA Bindepeptide und ihre Verwendungen
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Also Published As

Publication number Publication date
ES2135051T3 (es) 1999-10-16
DK0759032T3 (da) 1999-12-27
JPH10500667A (ja) 1998-01-20
US6019987A (en) 2000-02-01
GR3031811T3 (en) 2000-02-29
US5554506A (en) 1996-09-10
JP3451356B2 (ja) 2003-09-29
FI963781A (fi) 1996-09-23
FI963781A0 (fi) 1996-09-23
AU2187095A (en) 1995-10-09
CN1142177C (zh) 2004-03-17
NZ283543A (en) 1998-04-27
WO1995025739A1 (en) 1995-09-28
AU682956B2 (en) 1997-10-23
ATE183195T1 (de) 1999-08-15
EP0759032B1 (de) 1999-08-11
DE69511399D1 (de) 1999-09-16
CN1151167A (zh) 1997-06-04
US6353089B1 (en) 2002-03-05
EP0759032A4 (de) 1997-04-09
TW496875B (en) 2002-08-01
ZA952376B (en) 1995-12-14
CA2186005A1 (en) 1995-09-28
EP0759032A1 (de) 1997-02-26

Similar Documents

Publication Publication Date Title
DE69511399D1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
CA2186004A1 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
ATE201214T1 (de) Isolierte von tumor abstossenden vorläufer antigen mage-2 abgeleitete peptide und deren verwendung
DE69617440T2 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
CA2159098A1 (en) Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof
DE60039448D1 (de) Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
DE69433790T2 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
FI950887A0 (fi) MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt
EP0739350A4 (de) Fas-antigenbindender ligand
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
AU580350B2 (en) Process for synthesising peptides
UA66753C2 (en) Immunostimulator and method for its production
Townsend et al. Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
Parikh Purification and characterization of hemorrhagic factor from Crotalus atrox (Western diamondback rattlesnake) venom by high performance liquid chromatography (HPLC) and production of monoclonal antibody.
NZ329694A (en) Use of isolated cytolytic T cell clone specific for a complex of HLA-A2 and a peptide which complexes with HLA-A2 to treat cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition